{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:39:01Z","timestamp":1790753941010,"version":"4.1.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The coordinated efforts to stop the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) include massive immunization of the population at a global scale. The humoral immunity against COVID-19 is conferred by neutralizing antibodies (NAbs) that occur during the post-infection period and upon vaccination. Here, we provide robust data showing that potent neutralizing antibodies are induced in convalescent patients of SARS-CoV-2 infection who have been immunized with different types of vaccines, and patients with no previous history of COVID-19 immunized with a mixed vaccination schedule regardless of the previous infection. More importantly, we showed that a heterologous prime-boost in individuals with Ad5-nCoV (Cansino) vaccine induces higher NAbs levels in comparison to a single vaccination scheme alone.<\/jats:p>","DOI":"10.1371\/journal.pone.0269032","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:40:29Z","timestamp":1656092429000},"page":"e0269032","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico"],"prefix":"10.1371","volume":"17","author":[{"given":"Karla","family":"Cervantes-Luevano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid N.","family":"Espino-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Flores-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bernaldez-Sarabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Cabanillas-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahaziel","family":"Gasperin-Bulbarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Gonzalez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Comas-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4022-7405","authenticated-orcid":true,"given":"Alexei F.","family":"Licea-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"pone.0269032.ref001","doi-asserted-by":"crossref","unstructured":"Mexico: WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data n.d. https:\/\/covid19.who.int\/region\/amro\/country\/mx (accessed September 10, 2021).","DOI":"10.46945\/bpj.10.1.03.01"},{"key":"pone.0269032.ref002","unstructured":"Secretar\u00eda de Salud de M\u00e9xico. Informaci\u00f3n de la vacuna\u2013Vacuna Covid. Secretaria de Salud 2021. http:\/\/vacunacovid.gob.mx\/wordpress\/informacion-de-la-vacuna\/ (accessed September 11, 2021)."},{"key":"pone.0269032.ref003","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"A Manenti","year":"2020","journal-title":"Journal of Medical Virology"},{"key":"pone.0269032.ref004","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.21105\/joss.02815","article-title":"effectsize: Estimation of Effect Size Indices and Standardized Parameters","volume":"5","author":"MS Ben-Shachar","year":"2020","journal-title":"Journal of Open Source Software"},{"key":"pone.0269032.ref005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s guide to correlation coefficients","volume":"18","author":"H. Akoglu","year":"2018","journal-title":"Turkish Journal of Emergency Medicine"},{"key":"pone.0269032.ref006","unstructured":"Paulina Rodr\u00edguez-Maldonado A, Armando V\u00e1zquez-P\u00e9rez J, Taboada B, Boukadida C, Wong-Ar\u00e1mbula C, Ernestina Nu\u00f1ez-Garc\u00eda T, et al. Emergence and spread of the potential variant of interest (VOI) B.1.1.519 predominantly present in Mexico. n.d."},{"key":"pone.0269032.ref007","article-title":"Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App","author":"CH Sudre","year":"2020","journal-title":"MedRxiv"},{"key":"pone.0269032.ref008","article-title":"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases","volume":"6","author":"MdA Barek","year":"2020","journal-title":"Heliyon"},{"key":"pone.0269032.ref009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"KL F","year":"2017","journal-title":"Annual Review of Cell and Developmental Biology"},{"key":"pone.0269032.ref010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"C Manisty","year":"2021","journal-title":"The Lancet"},{"key":"pone.0269032.ref011","doi-asserted-by":"crossref","first-page":"n308","DOI":"10.1136\/bmj.n308","article-title":"Covid-19: People who have had infection might only need one dose of mRNA vaccine","volume":"372","author":"J. Wise","year":"2021","journal-title":"BMJ"},{"key":"pone.0269032.ref012","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19","volume":"325","author":"KE Stephenson","year":"2021","journal-title":"JAMA"},{"key":"pone.0269032.ref013","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/vaccines9080825","article-title":"Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"9","author":"A Bignucolo","year":"2021","journal-title":"Vaccines"},{"key":"pone.0269032.ref014","first-page":"585","volume":"385","author":"JL Bernal","year":"2021","journal-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant"},{"key":"pone.0269032.ref015","article-title":"Safety and Immunogenicity Report from the Com-COV Study\u2013a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine","author":"X Liu","year":"2021","journal-title":"SSRN Electronic Journal"},{"key":"pone.0269032.ref016","unstructured":"WHO. Tracking SARS-CoV-2 variants 2021. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ (accessed September 11, 2021)."},{"key":"pone.0269032.ref017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"R. Chen","year":"2021","journal-title":"Nat Med"},{"key":"pone.0269032.ref018","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Y Liu","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pone.0269032.ref019","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination","volume":"325","author":"VV Edara","year":"2021","journal-title":"JAMA"},{"key":"pone.0269032.ref020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"R. Chen","year":"2021","journal-title":"Nat Med"},{"key":"pone.0269032.ref021","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"P Wang","year":"2021","journal-title":"Nature"},{"key":"pone.0269032.ref022","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"D Planas","year":"2021","journal-title":"Nature Medicine"},{"key":"pone.0269032.ref023","doi-asserted-by":"crossref","unstructured":"Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, et al. Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. MedRxiv: The Preprint Server for Health Sciences 2020:2020.06.06.20123414. https:\/\/doi.org\/10.1101\/2020.06.06.20123414.","DOI":"10.1101\/2020.06.06.20123414"},{"key":"pone.0269032.ref024","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fimmu.2019.00180","article-title":"Sex Differences in Older Adults\u2019 Immune Responses to Seasonal Influenza Vaccination","volume":"0","author":"EA Voigt","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"pone.0269032.ref025","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050488","article-title":"Immune Response to COVID-19 mRNA Vaccine\u2014A Pilot Study","volume":"9","author":"A Lange","year":"2021","journal-title":"Vaccines"},{"key":"pone.0269032.ref026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"P Wang","year":"2021","journal-title":"Nature"},{"key":"pone.0269032.ref027","first-page":"1","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"2021","author":"KB Pouwels","year":"2021","journal-title":"Nature Medicine"},{"key":"pone.0269032.ref028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","volume":"29","author":"X Shen","year":"2021","journal-title":"Cell Host & Microbe"},{"key":"pone.0269032.ref029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines\u2013what\u2019s the future","volume":"135","author":"SC Gilbert","year":"2012","journal-title":"Immunology"},{"key":"pone.0269032.ref030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"JS Turner","year":"2021","journal-title":"Nature"},{"key":"pone.0269032.ref031","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"AM Borobia","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"no. 7860","key":"pone.0269032.ref032","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41586-021-01359-3","article-title":"Mix-and-match COVID vaccines trigger potent immune response","volume":"vol. 593","author":"E. Callaway","year":"2021","journal-title":"Nature"},{"issue":"no. 10","key":"pone.0269032.ref033","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/vaccines9101163","article-title":"The effects of heterologous immunization with prime\u2010boost covid\u201019 vaccination against sars\u2010cov\u20102","volume":"vol. 9","author":"T. C. Ho","year":"2021","journal-title":"Vaccines"},{"key":"pone.0269032.ref034","article-title":"Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose","author":"M. A. Gram","year":"2021","journal-title":"medRxiv"},{"key":"pone.0269032.ref035","doi-asserted-by":"crossref","first-page":"103761","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"vol. 75","author":"R. Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"key":"pone.0269032.ref036","article-title":"The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission","author":"D. W. Eyre","year":"2021","journal-title":"medRxiv"},{"key":"pone.0269032.ref037","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"AS Iyer","year":"2020","journal-title":"Science Immunology"},{"key":"pone.0269032.ref038","article-title":"Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","author":"Z Liu","year":"2021","journal-title":"BioRxiv"},{"key":"pone.0269032.ref039","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"L Stamatatos","year":"2021","journal-title":"Science"},{"key":"pone.0269032.ref040","first-page":"1","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"2021","author":"E Andreano","year":"2021","journal-title":"Nature"},{"issue":"no. 9","key":"pone.0269032.ref041","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"vol. 27","author":"T. Schmidt","year":"2021","journal-title":"Nature Medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:41:01Z","timestamp":1656092461000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269032"}},"subtitle":[],"editor":[{"given":"Paulo Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269032","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]}}}